Selegiline and rasagiline are "monoamine oxidase B inhibitors"
that have been used in treating Parkinson's disease. Selegiline
will be metabolized to amphetamine and methamphetamine, and can
subsequently lead to insomnia. On the other hand, rasagiline won't
be metabolized and it's also more potent.